Patents by Inventor Nicholas Moss
Nicholas Moss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11913228Abstract: Building panel assemblies for use in the construction of new homes, commercial buildings and extensions having rectangular structural insulated panel (SIP) (10), comprises a pair of spaced-apart containment boards (12?,12?) an inner insulating core (13) and a low profile peripheral external rigid frame (14), preferably of metal, e.g. steel, extending around the entire periphery of the spaced-apart boards (12?,12?).Type: GrantFiled: November 15, 2019Date of Patent: February 27, 2024Assignee: 4WALL IP DMCCInventors: Nicholas Edwards, Christopher Moss
-
Publication number: 20220107269Abstract: A refractometer includes an enclosure, a single use prism, a light source, and an index of refraction (IoR) sensor. The single use prism is removably disposed within the enclosure. The light source and IoR sensor are disposed within the housing and are configured to be repeatably used with a series of single use prisms of similar construction. One single use prism can be removed after being used, and a new single use prism can be installed in the enclosure for use with the same light source and IoR sensor as were used with the first prism.Type: ApplicationFiled: October 2, 2020Publication date: April 7, 2022Inventors: Marios LIAROMMATIS, Nicholas MOSS
-
Publication number: 20200368629Abstract: A remote-control vehicle is disclosed. The vehicle comprises a first wheel and a second wheel offset along the longitudinal axis of the vehicle. The vehicle further comprises a device adapted to apply a torque to the first wheel, a sensor configured to monitor the pitch angle of the vehicle, and a control module. The control module is configured to control the torque applied by the device to the first wheel in accordance with the monitored vehicle pitch angle so as to accelerate the vehicle while maintaining the vehicle pitch angle within a range of acute angles.Type: ApplicationFiled: November 21, 2018Publication date: November 26, 2020Inventor: Nicholas Moss
-
Patent number: 10422716Abstract: Methods and systems for leak testing flexible expandable bags are disclosed.Type: GrantFiled: December 8, 2016Date of Patent: September 24, 2019Assignee: Pall CorporationInventors: Nicholas Moss, Robin Hodges
-
Publication number: 20180164180Abstract: Methods and systems for leak testing flexible expandable bags are disclosed.Type: ApplicationFiled: December 8, 2016Publication date: June 14, 2018Inventors: Nicholas Moss, Robin Hodges
-
Publication number: 20170096641Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor.Type: ApplicationFiled: October 12, 2016Publication date: April 6, 2017Applicants: Vesta Therapeutics Inc., University of North Carolina at Chapel HillInventors: Lola M. REID, Nicholas MOSS, Mark E. FURTH, John W. LUDLOW, Andrew T. BRUCE
-
Publication number: 20140302601Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor.Type: ApplicationFiled: April 3, 2014Publication date: October 9, 2014Applicants: University of North Carolina at Chapel Hill, Vesta Therapeutics Inc.Inventors: Lola M. REID, Nicholas MOSS, Mark E. FURTH, John W. LUDLOW, Andrew T. BRUCE
-
Patent number: 8691523Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor.Type: GrantFiled: December 12, 2006Date of Patent: April 8, 2014Assignees: Vesta Therapeautics, Inc., University of North Carolina at Chapel HillInventors: Lola M. Reid, Nicholas Moss, Mark E. Furth, John W. Ludlow, Andrew T. Bruce
-
Publication number: 20100197015Abstract: Methods of isolating and cryopreserving progenitors from human liver are disclosed which include processing human liver tissue to provide a substantially single cell suspension comprising progenitors and non-progenitors of one or more cell lineages found in human liver; subjecting the suspension to a debulking step, which reduces substantially the number of non-progenitors in the suspension, and which provides a debulked suspension enriched in progenitors exhibiting one or more markers associated with at least one of the one or more cell lineages; and selecting from said debulked suspension those cells, which themselves, their progeny, or more mature forms thereof express one or more markers associated with at least one of the one or more cell lineages. Among these markers are CD14, CD34, CD38, CD45, and ICAM. Hepatic progenitors are characterized as being 6-15? in diameter, diploid, glycophorin A?, CD45?, AFP+++, ALB+, ICAM+, and with subpopulations varying in expression of CD14+. CD34++, CD38++, CD117+.Type: ApplicationFiled: January 28, 2010Publication date: August 5, 2010Inventors: Lola M. Reid, Nicholas Moss, Hiroshi Kubota
-
Patent number: 7413897Abstract: Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver. Human proximal hepatic stem cells give rise to biliary and hepatocyte committed progenitors. Primitive and proximal stem cells are the primary stem cells for the human liver. Human primitive hepatic stem cells may be isolated by immunoselection from human livers or culturing human liver cells under conditions which select for a human primitive hepatic stem cell. Proximal hepatic stem cells may be isolated by immunoselection, or by culturing human liver cells under conditions which include a developmental factor.Type: GrantFiled: March 14, 2003Date of Patent: August 19, 2008Assignees: University of North Carolina at Chapel Hill, Vesta Therapeutics, Inc.Inventors: Lola M. Reid, Nicholas Moss, Mark Furth, John W. Ludlow, Andrew T. Bruce
-
Publication number: 20050148072Abstract: Methods of isolating and cryopreserving progenitors from human liver are disclosed which include processing human liver tissue to provide a substantially single cell suspension comprising progenitors and non-progenitors of one or more cell lineages found in human liver; subjecting the suspension to a debulking step, which reduces substantially the number of non-progenitors in the suspension, and which provides a debulked suspension enriched in progenitors exhibiting one or more markers associated with at least one of the one or more cell lineages; and selecting from said debulked suspension those cells, which themselves, their progeny, or more mature forms thereof express one or more markers associated with at least one of the one or more cell lineages. Among these markers are CD14, CD34, CD38, CD45, and ICAM. Hepatic progenitors are characterized as being 6-15? in diameter, diploid, glycophorin A?, CD45?, AFP+++, ALB+, ICAM+, and with subpopulations varying in expression of CD14+. CD34++, CD38++, CD117+.Type: ApplicationFiled: September 21, 2004Publication date: July 7, 2005Applicant: The University of North Carolina at Chapel HillInventors: Lola Reid, Nicholas Moss, Hiroshi Kubota
-
Publication number: 20020182188Abstract: Methods of isolating and cryopreserving progenitors from human liver are disclosed which include processing human liver tissue to provide a substantially single cell suspension comprising progenitors and non-progenitors of one or more cell lineages found in human liver; subjecting the suspension to a debulking step, which reduces substantially the number of non-progenitors in the suspension, and which provides a debulked suspension enriched in progenitors exhibiting one or more markers associated with at least one of the one or more cell lineages; and selecting from said debulked suspension those cells, which themselves, their progeny, or more mature forms thereof express one or more markers associated with at least one of the one or more cell lineages. Among these markers are CD14, CD34, CD38, CD 45, and ICAM.Type: ApplicationFiled: January 19, 2000Publication date: December 5, 2002Inventors: Lola M. Reid, Nicholas Moss, Hiroshi Kubota